目的PRESENT（Physicians’Routine Evaluation of Safety and Efficacy of NovoMix30Therapy）为多中心、前瞻性、开放性国际多中心临床观察研究，目的是评价口服药降糖控制不良的2型糖尿病患者使用预混人胰岛素类似物（诺和锐~30）的...
详细信息
目的PRESENT（Physicians’Routine Evaluation of Safety and Efficacy of NovoMix30Therapy）为多中心、前瞻性、开放性国际多中心临床观察研究，目的是评价口服药降糖控制不良的2型糖尿病患者使用预混人胰岛素类似物（诺和锐~30）的有效性、安全性和治疗满意度。本研究来源于PRESENT中国区研究结果。方法共4754例以往使用口服降糖药治疗的2型糖尿病患者参与了本研究。参与研究的医生按照产品说明书处方诺和锐30特充，并在基线和治疗后3个月分别收集患者的临床数据。结果患者基线平均HbAlc（9．09±1．70）％，体重指数（BMI）为（24．30±2．68）kg／In。，年龄（54．63±10．94）岁，糖尿病病程（5．46±4．17）年。治疗开始和3个月后，诺和锐30平均日剂量分别为（0．43±0．14）U／kg和（0．48±0．15）U／kg。3个月后，平均HbA1C、空腹血糖（FPG）和餐后血糖（PPG）显著降低[分别下降（2．04±1．57）％、（3．51±2．55）mmol／L、（6．51±4．02）mmol／L，均P〈0．01]，49．4％的患者达到HbA1C〈7％的治疗标准。总体低血糖事件（件／患者年）从基线时10．098下降至3．810，重度低血糖事件从0．787下降至0．126，夜间低血糖事件从2．356下降至0．547。与以往治疗相比，超过99％的医生和患者对使用诺和锐30特充四治疗表示“满意”或“非常满意”。结论口服降糖药血糖控制不良的2型糖尿病患者，使用诺和锐30特充可有效改善血糖控制水平，提高治疗达标率，同时降低低血糖发生风险。
Objective To detect the relationship between the polymorphism of the glycogen-targeting regulatory subunit of the skeletal muscle glycogen-associated protein phosphatase 1 (PPP1R3) gene and type 2 diabetes by case-con...
详细信息
Objective To detect the relationship between the polymorphism of the glycogen-targeting regulatory subunit of the skeletal muscle glycogen-associated protein phosphatase 1 (PPP1R3) gene and type 2 diabetes by case-control study. Methods We genotyped the PPP1R3 gene Asp905Tyr polymorphism and a common 3'-untranslated region AT (AU)-rich element (ARE) polymorphism in 101 type 2 diabetic patients and 101controls by oligonucleotide ligation assay (OLA) and polyacrylamide gel elecrophoresis, respectively. Results Subjects with Tyr/Tyr genotypes whose body mass index (BMI)<25 were used as the reference group. Those whose BMI25 with Asp905 had a 3.66-fold increase (95% CI: 1.48-9.06, P=0.005) in type 2 diabetes risk. No association was found between 3'UTR ARE polymorphism and type 2 diabetes mellitus (OR=1.15; 95% CI: 0.62-2.14, P=0.65). Conclusion A joint effect between the Asp905 and BMI increases the risk of type 2 diabetes, and Asp905Tyr and ARE polymorphism of PPP1R3 gene are not the major diabetogenic gene variants in Chinese population.
暂无评论